ERBB2 K755S

CI-VAR-00002179Explore in graph →CIViC 1314

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
ERBB2 K755S	Trastuzumab	Predictive	B	Supports Resistance	3	submitted	EID3026 3/18 metastatic HER2-positive breast cancers had the K755S mutation after one year of adjuvant trastuzumab. K755S was undetectable in the corresponding primary tumors. In vitro experiments showed that… (full text at CIViC) PMID 27697991 · Zuo et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.